Skip to main content
SpringerLink
Log in

Pharmacogenetics

  • Chapter
  • First Online:
Textbook of Personalized Medicine

  • 2435 Accesses

Abstract

Pharmacogenetics, a term recognized in pharmacology in the pre-genomic era, is the study of influence of genetic factors on action of drugs as opposed to genetic causes of disease. Now it is the study of the linkage between the individual’s genotype and the individual’s ability to metabolize a foreign compound. The pharmacological effect of a drug depends on pharmacodynamics (interaction with the target or the site of action) and pharmacokinetics (absorption, distribution and metabolism). It also covers the influence of various factors on these processes. Drug metabolism is one of the major determinants of drug clearance and the factor that is most often responsible for interindividual differences in pharmacokinetics. Pharmacogenetics links genotype and phenotype as shown in Fig. 4.1.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Chen P, Lin JJ, Lu CS, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med. 2011;364:1126–33.

    Article  CAS  PubMed  Google Scholar 

  • Csoka AB, Szyf M. Epigenetic side-effects of common pharmaceuticals: a potential new field in medicine and pharmacology. Med Hypotheses. 2009;73:770–80.

    Article  CAS  PubMed  Google Scholar 

  • Damani SB, Topol EJ. The case for routine genotyping in dual-antiplatelet therapy. J Am Coll Cardiol. 2010;56:109–11.

    Article  PubMed  Google Scholar 

  • Ellis KJ, Stouffer GA, McLeod HL, Lee CR. Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. Pharmacogenomics. 2009;10:1799–817.

    Article  CAS  PubMed  Google Scholar 

  • Ford NF. Clopidogrel resistance: pharmacokinetic or pharmacogenetic? J Clin Pharmacol. 2009;49:506–12.

    Article  CAS  PubMed  Google Scholar 

  • Frueh FW, Amur S, Mummaneni P, et al. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use. Pharmacotherapy. 2008;28:992–8.

    Article  PubMed  Google Scholar 

  • Giorgi MA, Caroli C, Arazi HC, Di Girolamo G. Pharmacogenomics and adverse drug reactions: the case of statins. Expert Opin Pharmacother. 2011;12:1499–509.

    Article  CAS  PubMed  Google Scholar 

  • Goldstein JI, Fredrik Jarskog L, Hilliard C, et al. Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles. Nat Commun. 2014;5:4757.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Holmes Jr DR, Dehmer GJ, Kaul S, et al. ACCF/AHA clopidogrel clinical alert: approaches to the FDA “Boxed Warning”. J Am Coll Cardiol. 2010;56:321–41.

    Article  CAS  PubMed  Google Scholar 

  • Holmes MV, Perel P, Shah T, et al. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events. a systematic review and meta-analysis. JAMA. 2011;306:2704–14.

    Article  CAS  PubMed  Google Scholar 

  • Ingelman-Sundberg M. Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. N Engl J Med. 2008;358:637–9.

    Article  CAS  PubMed  Google Scholar 

  • Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther. 2007;116:496–526.

    Article  CAS  PubMed  Google Scholar 

  • Jain KK. Biomarkers: technologies, markets and companies. Basel: Jain Pharma Biotech; 2015.

    Google Scholar 

  • Lee MT, Hung SI, Wei CY, Chen YT. Pharmacogenetics of toxic epidermal necrolysis. Expert Opin Pharmacother. 2010;11:2153–62.

    Article  CAS  PubMed  Google Scholar 

  • Lee SJ. Clinical application of CYP2C19 pharmacogenetics toward more personalized medicine. Front Genet. 2013;3:318.

    Article  PubMed Central  PubMed  Google Scholar 

  • Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354–62.

    Article  CAS  PubMed  Google Scholar 

  • McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011;364:1134–43.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Momary KM, Dorsch MP, Bates ER. Genetic causes of clopidogrel nonresponsiveness: which ones really count? Pharmacotherapy. 2010;30:265–74.

    Article  CAS  PubMed  Google Scholar 

  • Mora S, Glynn RJ, Hsia J, et al. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation. 2010;121:1069–77.

    Article  CAS  PubMed  Google Scholar 

  • Paré G, Mehta SR, Yusuf S, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med. 2010;363:1704–14.

    Article  PubMed  Google Scholar 

  • Pereira CV, Moreira AC, Pereira SP, et al. Investigating drug-induced mitochondrial toxicity: a biosensor to increase drug safety? Curr Drug Saf. 2009;4:34–54.

    Article  CAS  PubMed  Google Scholar 

  • Pirmohamed M, Burnside G, Eriksson N, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. 2013;369:2294–303.

    Article  CAS  PubMed  Google Scholar 

  • Ray LA, Miranda Jr R, MacKillop J, et al. A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers. Exp Clin Psychopharmacol. 2009;17:122–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Reynolds KK, Valdes R, Hartung BR, Linder LW. Individualizing warfarin therapy. Pers Med. 2007;4:11–31.

    Article  CAS  Google Scholar 

  • SEARCH Collaborative Group, Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy – a genomewide study. N Engl J Med. 2008;359:789–99.

    Article  Google Scholar 

  • Shuldiner AR, O’Connell JR, Biden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302:849–57.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation. 2010;121:512–8.

    Article  CAS  PubMed  Google Scholar 

  • Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360:363–75.

    Article  CAS  PubMed  Google Scholar 

  • Singer JB, Lewitzky S, Lero E, et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet. 2010;42:711–4.

    Article  CAS  PubMed  Google Scholar 

  • Sissung TM, Mross K, Steinberg SM, et al. Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenias. Eur J Cancer. 2006;42:2893–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Takeuchi F, McGinnis R, Bourgeois S, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 2009;5:e1000433.

    Article  PubMed Central  PubMed  Google Scholar 

  • The International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360:753–64.

    Article  PubMed Central  Google Scholar 

  • Thompson AJ, Newman WG, Elliott RA, et al. The cost-effectiveness of a pharmacogenetic test: a trial-based evaluation of TPMT genotyping for azathioprine. Value Health. 2014;17:22–33.

    Article  PubMed  Google Scholar 

  • Verbelen M, Collier DA, Cohen D, et al. Establishing the characteristics of an effective pharmacogenetic test for clozapine induced agranulocytosis. BioRxiv. 2014. doi:http://dx.doi.org/10.1101/010900

Download references

Author information

Authors and Affiliations

  1. Jain PharmaBiotech, Basel, Switzerland

    Kewal K. Jain

Authors
  1. Kewal K. Jain
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Jain, K.K. (2015). Pharmacogenetics. In: Textbook of Personalized Medicine. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-2553-7_4

Download citation

Publish with us

Policies and ethics

Search

Navigation